Pharsight

1. Oxtellar Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7722898	SUPERNUS PHARMS	Modified-release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US9370525	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US8617600	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US9855278	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US10220042	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US9119791	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US7910131	SUPERNUS PHARMS	Method of treating seizures using modified release formulations of oxcarbazepine	Apr, 2027 (3 years from now)
US11166960	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US8821930	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)
US9351975	SUPERNUS PHARMS	Modified release preparations containing oxcarbazepine and derivatives thereof	Apr, 2027 (3 years from now)

Drugs and Companies using OXCARBAZEPINE ingredient

Market Authorisation Date: 19 October, 2012

Treatment: Treatment of partial-onset seizures

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
600 mg	20 Mar, 2013	1		13 Apr, 2027	Extinguished
150 mg and 300 mg	12 Apr, 2013	1		13 Apr, 2027	Extinguished

Strength	Dosage	Availability
150MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
300MG	TABLET, EXTENDED RELEASE;ORAL	Prescription
600MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

OXTELLAR XR family patents

2. Qelbree patents expiration

Patent	Proceeding Filing Date	Status	Respondent	Petitioner

US11324753	February, 2021	Decision	Supernus Pharmaceuticals, Inc.

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11324753	SUPERNUS PHARMS	Method of treatment of attention deficit/hyperactivity disorder (ADHD)	Sep, 2029 (5 years from now)
US11458143	SUPERNUS PHARMS	NA	Sep, 2029 (5 years from now)
US9603853	SUPERNUS PHARMS	Formulations of viloxazine	Feb, 2033 (9 years from now)
US9358204	SUPERNUS PHARMS	Formulations of viloxazine	Feb, 2033 (9 years from now)
US9662338	SUPERNUS PHARMS	Formulations of viloxazine	Feb, 2033 (9 years from now)

Drug Exclusivity	Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Apr 2, 2026
New Patient Population (NPP)	Apr 29, 2025

Drugs and Companies using VILOXAZINE HYDROCHLORIDE ingredient

NCE-1 date: 2025-04-02

Market Authorisation Date: 02 April, 2021

Treatment: For the treatment of attention deficit hyperactivity disorder (adhd); U-727: for the treatment of attention deficit hyperactivity disorder (adhd)

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 150MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 200MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

QELBREE family patents

3. Trokendi Xr patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8877248	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (4 years from now)
US9555004	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (4 years from now)
US10314790	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (4 years from now)
US8663683	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (4 years from now)
US9622983	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (4 years from now)
US8298580	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (4 years from now)
US8992989	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (4 years from now)
US8889191	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (4 years from now)
US9549940	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Nov, 2027 (4 years from now)
US8298576	SUPERNUS PHARMS	Sustained-release formulations of topiramate	Apr, 2028 (4 years from now)

Drugs and Companies using TOPIRAMATE ingredient

Market Authorisation Date: 16 August, 2013

Treatment: Use of trokendi xr for prophylactic treatment of migraine; Treatment of epilepsy; Use of trokendi xr for the treatment of epilepsy

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
200 mg	03 Apr, 2014	1		18 Mar, 2029	Extinguished
25 mg, 50 mg, and 100 mg	12 May, 2014	1	24 Nov, 2017	18 Mar, 2029	Extinguished Non-Forfeiture Deferred

Strength	Dosage	Availability
25MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
50MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
100MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
200MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription